RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

Nexalin Technology (NXL) signed a 10-year exclusive distribution agreement with Inovanexa Medical Technologies for Brazil and six other South American countries. The deal includes a 100-device commercialization program, local manufacturing, and revenue-sharing. Nexalin Sync, approved for anxiety, depression, and insomnia, will be distributed across 300 million people.

Nexalin Technology (NXL) reported positive eight-week clinical trial results for its non-invasive DIFS neurostimulation in adults with generalized anxiety disorder and comorbid insomnia. Conducted at the University of São Paulo’s Institute of Psychiatry, the study used a 15 mA, 77.5 Hz protocol across 20 40-minute sessions. Nexalin said the end-of-treatment anxiety response rate was 77.8% (HAM-A drop by Session 5 and maintained at follow-up), with no serious adverse events.

Arvinas (ARVN) will present Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 targets LRRK2, a protein linked to Parkinson’s and PSP. The presentations will include biomarker and oculomotor data. Arvinas is a clinical-stage biotech company focused on protein degradation therapies.

Infosys (INFY) stock rose 6.27% after extending its AI partnership with ABN AMRO, enhancing the bank's digital transformation. The company's ADRs have seen volatility, trading between $11.35 and $11.50. Infosys reports strong fundamentals, including a P/E ratio of 13.3, ROE of 12.56%, and a 4.8% dividend yield. The stock's recent decline contrasts with its strategic AI deal and solid financials.